Ongoing clinical trials are also examining how fiber supplementation may help augment IL-17 therapies for autoimmune disease (NCT06055699, NCT05812157), and the data in this report suggest that similar approaches that take into consideration an individual’s gut microbiome status should be incorporated to maximize possible therapeutic benefits in the setting of dementia pathophysiology. Here, IL17A is linked to autoimmune disease.